Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

AIMS: In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined whether this benefit was consistent in relation to background HF therapy. METHODS AND RESULTS: In this post hoc anal...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur Heart J
Autori principali: Docherty, Kieran F, Jhund, Pardeep S, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, DeMets, David L, Sabatine, Marc S, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna Maria, Desai, Akshay S, Diez, Mirta, Howlett, Jonathan G, Katova, Tzvetana, Ljungman, Charlotta E A, O’Meara, Eileen, Petrie, Mark C, Schou, Morten, Verma, Subodh, Vinh, Pham Nguyen, Solomon, Scott D, McMurray, John J V
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Fast Track Clinical Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327533/
https://ncbi.nlm.nih.gov/pubmed/32221582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa183
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi